Chinese Pharmas Develop Generic Of GSK’s Relenza
This article was originally published in PharmAsia News
A pair of Chinese pharmaceutical companies and a team of scientists report success in developing a way to produce Relenza (zanamivir) locally for treating avian influenza. U.K.-based GlaxoSmithKline had licensed the drug to Materia Medica and Nanjing Effact Pharm Drug Development, but did not supply the technology, relying on them to reproduce the drug. The China-made version has received permission to undergo clinical trials. Roche, which makes the rival bird flu drug Tamiflu (oseltamivir), has granted licenses to two other Chinese pharmas to make generics. (Click here for more
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.